The Efficacy, Safety, and Immunogenicity of Switching Between Reference Biopharmaceuticals and Biosimilars: A Systematic Review von Barbier, Liese, Ebbers, Hans C., Declerck, Paul, Simoens, Steven, Vulto, Arnold G., Huys, Isabelle

Volltext

Are we ready to close the discussion on the interchangeability of biosimilars? von Ebbers, Hans C., Schellekens, Huub

Volltext

Real-World Evidence on Etanercept Biosimilar SB4 in Etanercept-Naïve or Switching Patients: A Systematic Review von Ebbers, Hans C., Pieper, Burkhard, Issa, Amine, Addison, Janet, Freudensprung, Ulrich, Rezk, Mourad F.

Volltext

A Retrospective Analysis of the Potential Impact of Differences in Aggregates on Clinical Immunogenicity of Biosimilars and their Reference Products von Fernandez‐Mendivil, Cristina, Kinsella, Niamh M., Ebbers, Hans C.

Volltext

Biosimilars: In support of extrapolation of indications von Ebbers, Hans C.

Volltext

Measures of biosimilarity in monoclonal antibodies in oncology: the case of bevacizumab von Ebbers, Hans C., van Meer, Peter J.K., Moors, Ellen H.M., Mantel-Teeuwisse, Aukje K., Leufkens, Hubert G.M., Schellekens, Huub

Volltext

Interchangeability, immunogenicity and biosimilars von Ebbers, Hans C, Crow, Stacy A, Vulto, Arnold G, Schellekens, Huub

Volltext

Demonstration of Physicochemical and Functional Similarity of the Biosimilar BAT1806/BIIB800 to Reference Tocilizumab von Liu, Yujie, Xie, Jianhua, Li, Zhuxiang, Mei, Xiong, Cao, Di, Li, Shengfeng, Engle, Linda, Liu, Suli, Ebbers, Hans C., Liu, Cuihua

Volltext

Correction to: Demonstration of Physicochemical and Functional Similarity of the Biosimilar BAT1806/BIIB800 to Reference Tocilizumab von Liu, Yujie, Xie, Jianhua, Li, Zhuxiang, Mei, Xiong, Cao, Di, Li, Shengfeng, Engle, Linda, Liu, Suli, Ebbers, Hans C., Liu, Cuihua

Volltext

Controversies in Establishing Biosimilarity: Extrapolation of Indications and Global Labeling Practices von Ebbers, Hans C., Chamberlain, Paul

Volltext

An Introduction to Biosimilars for the Treatment of Retinal Diseases: A Narrative Review von Hariprasad, Seenu M., Gale, Richard P., Weng, Christina Y., Ebbers, Hans C., Rezk, Mourad F., Tadayoni, Ramin

Volltext

Batch-to-Batch Consistency of SB4 and SB2, Etanercept and Infliximab Biosimilars von Ebbers, Hans C., Fehrmann, Bjørn, Ottosen, Mette, Hvorslev, Niels, Høier, Pia, Hwang, Jae-Woong, Chung, Jinhan, Lim, Hyoung Taek, Lee, Shinjung, Hong, Juyoung, Rezk, Mourad Farouk

Volltext

Contribution of animal studies to evaluate the similarity of biosimilars to reference products von van Meer, Peter J.K., Ebbers, Hans C., Kooijman, Marlous, Gispen-de Wied, Christine C., Silva-Lima, Beatriz, Moors, Ellen H.M., Schellekens, Huub

Volltext

Interchangeability. An insurmountable fifth hurdle? von Ebbers, Hans C, Chamberlain, Paul

Volltext

Characteristics of product recalls of biopharmaceuticals and small-molecule drugs in the USA von Ebbers, Hans C., Tienda, Nina Fuentes de, Hoefnagel, Marcel C., Nibbeling, Ria, Mantel-Teeuwisse, Aukje K.

Volltext

Effective pharmaceutical regulation needs alignment with doctors von Ebbers, Hans C., Pieters, Toine, Leufkens, Hubert G., Schellekens, Huub

Volltext

Licensing failure in the European decentralised procedure von Langedijk, Joris, Ebbers, Hans C., Mantel-Teeuwisse, Aukje K., Kruger-Peters, Alexandra G., Leufkens, Hubert G.M.

Volltext

The effect of exposure misclassification in spontaneous ADR reports on the time to detection of product-specific risks for biologicals: a simulation study von Vermeer, Niels S., Ebbers, Hans C., Straus, Sabine M. J. M., Leufkens, Hubert G. M., Egberts, Toine C. G., De Bruin, Marie L.

Volltext

An analysis of marketing authorisation applications via the mutual recognition and decentralised procedures in Europe von Ebbers, Hans C., Langedijk, Joris, Bouvy, Jacoline C., Hoekman, Jarno, Boon, Wouter P. C., de Jong, Jean Philippe, De Bruin, Marie L.

Volltext

Are we ready to close the discussion on the interchangeability of biosimilars? von Ebbers, Hans C, Schellekens, Huub

Volltext